Derma Sciences' Medihoney posted double-digit sales growth during the 1st quarter and the wound care product continues to gather fans around the world, says the company's CEO Ed Quilty. Quilty says the company added nearly 30 people to his sales and marketing staff in the first quarter of 2014 to introduce more clinicians to Medihoney. He also says the company's wound healing and scar reduction drug DSC 127 is in phase III testing and the company should have a data readout at the end of 2015. Finally, Quilty says the company is growing its presence in Europe and now has distributors in more than 20 countries.

If you liked this article you might like

Integra Scoops Up JNJ's Codman Neurosurgery for $1.05 Billion

Integra Scoops Up JNJ's Codman Neurosurgery for $1.05 Billion

Derma Sciences Soars Almost 40% on Buyout by Integra

Derma Sciences Soars Almost 40% on Buyout by Integra

Derma Sciences (DSCI) Stock Falls After Ending Drug Trial

Derma Sciences (DSCI) Stock Falls After Ending Drug Trial

Sell These 7 Health Care Supplies Companies Now

Sell These 7 Health Care Supplies Companies Now

Insider Trading Alert - DGI, CME And DSCI Traded By Insiders

Insider Trading Alert - DGI, CME And DSCI Traded By Insiders